|Day's Range||0.7000 - 0.7000|
67.8% growth in HIFU revenue through the nine month period ended September 30 over the comparable period in 201848.2% Gross margin for the nine month period ended September 30.
EDAP TMS SA (EDAP) (“the Company”), the global leader in therapeutic ultrasound, announced today the introduction of a new concept of Endourology Platform during the WCE congress, which is being held in Abu Dhabi, October 29 – November 2, 2019. Endo-UP® is a new conceptual product designed for the management of urinary stones. This unique all-in-one concept will allow surgeons to choose from among multiple stone treatment strategies, including Extracorporeal Shockwave Lithotripsy (ESWL), Ureteroscopy (URS), Percutaneous Nephrolithotomy (PCNL), or even a combination of therapeutic approaches.
Company to host conference call and webcast on Thursday, November 14, at 8:30 am EDT LYON, France, October 24, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in.
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Today we are going to look at EDAP TMS S.A. (NASDAQ:EDAP) to see whether it might be an attractive investment...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 28) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down ...
Third consecutive profitable quarter Positive reimbursement decision by the American Medical Association announced in June Significant improvement in gross profit margin from.
LYON, France, July 25, 2019 - EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced preliminary unaudited revenues for the second quarter ended June 30, 2019. Preliminary total revenue for the second quarter 2019 totaled EUR 12.5 million, a 45% year-over-year increase. Growth in total revenue includes strong 98% growth in HIFU sales, which totaled EUR 4.6 million for the second quarter.
EDAP TMS SA (EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that the American Medical Association’s (“AMA”) CPT® Editorial Panel, at its May 2019 meeting, accepted EDAP’s application to establish a new Category 1 CPT code that will facilitate reimbursement for the ablation of malignant prostate tissue with HIFU technology. The CPT code description selected by the Panel is “Ablation of malignant prostate tissue, transrectal, with high intensity focused ultrasound (HIFU) including ultrasound guidance.” The code will be included in the next CPT® Codebook and be effective on January 1, 2021.
EDAP Reports 2019 First Quarter Results HIFU revenue growth of 58.6% year-over-yearProfitable for second consecutive quarter Total Q1 revenues of EUR 10.1 million;.
is expected to report earnings of 2 cents a share on sales of $14.4 million after the market closes on on May. 15, based on a FactSet survey of two analysts. The company's American depository receipts have risen 49.5% since the company last reported earnings on Apr. 1. Quarterly estimates have fallen less than 1 cent a share in the past month.
Company to host conference call and webcast on Thursday, May 16, at 8:30 am EDT LYON, France, May 2, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic.
LYON, France, April 29, 2019 -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, announced today that it will demonstrate the capabilities of its range of minimally-invasive therapeutic ultrasound products, including its breakthrough Focal One® HIFU (High Intensity Focused Ultrasound) advanced robotic technology for the targeted ablation of prostate tissue, at booth #2211 at the American Urology Association ("AUA") Annual Meeting, which is being held May 3-6, 2019, at Mc Cornick Place, in Chicago, IL. This will be the first time that EDAP is showcasing Focal One at AUA.
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! Take, for example EDAP TMS S.A. (NA...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / EDAP TMS SA Sponsored ADR (NASDAQ: EDAP ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 2, 2019 at 8:30 ...
Reports record revenues for the fifth consecutive year Record fiscal year 2018 revenues of €39.2 million Q4 2018 HIFU net sales increased 79% year-over-year Profitable.